中国药物经济学2026，Vol.21Issue(2)：15-21,7.DOI:10.12010/j.issn.1673-5846.2026.02.003
替雷利珠单抗一线治疗晚期非鳞非小细胞肺癌的临床综合评价
Clinical Comprehensive Evaluation of First-line Treatment with Tislelizumab for Advanced Non-squamous Non-small Cell Lung Cancer
摘要
Abstract
Objective To conduct a comprehensive clinical evaluation of tislelizumab as a first-line therapy for advanced non-sqNSCLC,so as to provide recommendations for clinical treatment and evidence for optimizing the drug catalog and medical insurance reimbursement policies.Methods In accordance with the Technical Guidelines for Comprehensive Clinical Evaluation of Antitumor Drugs(2021 Trial Version),a comprehensive clinical evaluation of tislelizumab in first-line treatment of advanced non-sqNSCLC was performed from six dimensions(effectiveness,safety,economy,innovation,appropriateness and accessibility)based on the methodologies of evidence-based pharmacy,pharmacoeconomics and health technology assessment,using relevant literature data,public data and questionnaires.Results In terms of effectiveness,compared with other immune checkpoint inhibitors(ICIs),tiranizumab has no significant advantage in the median progression-free survival(mPFS)dimension,but it outperforms most other regimens in the median overall survival(mOS)dimension and the objective response rate(ORR)dimension.In terms of safety,there is no significant difference from other ICIs.In terms of economics,it has certain cost-effectiveness advantages in China.After medical insurance reimbursement,the burden on patients is relatively light and the drug accessibility is high.Conclusion Tislelizumab is safe,effective,highly innovative,cost-effective,convenient and accessible as a first-line therapy for advanced non-sqNSCLC,and thus can be recommended as a routine treatment option for advanced non-sqNSCLC in medical institutions.关键词
替雷利珠单抗/非鳞状非小细胞肺癌/临床综合评价Key words
Tislelizumab/Non-squamous non-small cell lung cancer/Clinical comprehensive evaluation分类
医药卫生引用本文复制引用
黄光明,冯丹,黄恩平,梁博鑫,张宏亮..替雷利珠单抗一线治疗晚期非鳞非小细胞肺癌的临床综合评价[J].中国药物经济学,2026,21(2):15-21,7.基金项目
白求恩公益基金会"耀动神州-药学科研能力建设基金"项目 （）
